# US 2010/0063161 A1 · Treatment of pervasive developmental disorders with redox-active therapeutics

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0063161 A1
- Document ID: US20100063161A1
- Status: Published application
- Kind: A1
- Application number: 12/555,700
- Filed: 2009-09-08
- Published: 2010-03-11
- Earliest claimed: 2008-09-10
- Assignees: Edison Pharmaceuticals, Inc.
- Inventors: Guy M. MILLER; Viktoria KHEIFETS
- Web page: https://patentgrep.com/patent/US20100063161A1

## CPC

- A61K 31/122: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A23L 33/10: using additives (addition of substantially indigestible substances A23L33/21)
- A23L 33/40: {Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula}
- A61K 31/05: Phenols {(cannabinoids A61K31/658)}
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07C 39/08: Dihydroxy benzenes; Alkylated derivatives thereof
- C07C 50/02: with monocyclic quinoid structure
- C07C 50/06: with unsaturation outside the quinoid structure
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- C07C 2601/16: the ring being unsaturated
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION

## Abstract

Methods of treating or suppressing pervasive developmental disorders (PDDs) including; autistic disorder, Asperger's syndrome, childhood disintegrative disorder (CDD), Rett's disorder, and PDD-not otherwise specified (PDD-NOS) or attention deficit/hyperactivity disorder (ADHD) comprising administering to a subject in need thereof a therapeutically effective amount of one or more compounds as disclosed herein.

## Claims

### Claim 1

A composition for reducing the symptoms associated with, or for treating or suppressing a pervasive developmental disorder (PDD) or attention deficit/hyperactivity disorder (ADHD), in a patient in need of such treatment comprising one or more compounds of Formula I, Formula II, Formula III, Formula IV, Formula V, or Formula VI or mixtures thereof,
wherein,
the bonds indicated with a dashed line are all single bonds or are all double bonds;
R1, R2, and R3 are independently selected from H, (C1-C6)alkyl, (C1-C6)haloalkyl, (C1-C6)alkoxy, halogen and CN;
or a stereoisomer, a mixture of stereoisomers, a solvate or a hydrate thereof.

### Claim 2 (depends on 1)

The composition according to claim 1, comprising one or more compounds of Formula Ia, Formula IIa, Formula IIIa, Formula IVa, Formula Va, Formula VIa, or mixtures thereof,
or a stereoisomer, a mixture of stereoisomers, a solvate or a hydrate thereof.

### Claim 3 (depends on 2)

The composition according to claim 2, wherein the compound is selected from 2-(3-hydroxy-3,7,11,15-tetramethylhexadeca-6,10,14-trienyl)-3,5,6-trimethylcyclohexa-2,5-dione-1,4-dione (Ib); 2-((3R,6E,10E)-3-hydroxy-3,7,11,15-tetramethylhexadeca-6,10-dienyl)-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione (Ib-R); 2-((3S,6E,10E)-3-hydroxy-3,7,11,15-tetramethylhexadeca-6,10-dienyl)-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione (113-S); 2-(3-hydroxy-3,7,11,15-tetramethylhexadecyl)-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione (Ic); 2-((3R,7R,11R)-3-hydroxy-3,7,11,15-tetramethylhexadecyl)-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione (Ic-RRR); 2-((3S,7R,11R)-3-hydroxy-3,7,11,15-tetramethylhexadecyl)-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione (Ic-SRR); 2-((3R,7S,11R)-3-hydroxy-3,7,11,15-tetramethylhexadecyl)-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione (Ic-RSR); 2-((3R,7R,11S)-3-hydroxy-3,7,11,15-tetramethylhexadecyl)-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione (Ic-RRS); 2-((3S,7S,11R)-3-hydroxy-3,7,11,15-tetramethylhexadecyl)-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione (Ic-SSR); 2-((3S,7R,11S)-3-hydroxy-3,7,11,15-tetramethylhexadecyl)-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione (Ic-SRS); 2-((3R,7S,11S)-3-hydroxy-3,7,11,15-tetramethylhexadecyl)-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione (Ic-RSS); 2-((3S,7S,11S)-3-hydroxy-3,7,11,15-tetramethylhexadecyl)-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione (Ic-SSS); 2,3,5-trimethyl-6-(3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraenyl)cyclohexa-2,5-diene-1,4-dione (III-b); 2,3,5-trimethyl-6-(3,7,11,15-tetramethylhexadecyl)cyclohexa-2,5-diene-1,4-dione (IIIc); 2,3,5-trimethyl-6-(3R,7R,11R)-3,7,11,15-tetramethylhexadecyl)cyclohexa-2,5-diene-1,4-dione (IIIc-RRR); 2,3,5-trimethyl-6-((3S,7R,11R)-3,7,11,15-tetramethylhexadecyl)cyclohexa-2,5-diene-1,4-dione (IIIc-SRR); 2,3,5-trimethyl-6-((3R,7S,11R)-3,7,11,15-tetramethylhexadecyl)cyclohexa-2,5-diene-1,4-dione (IIIc-RSR); 2,3,5-trimethyl-6-((3R,7R,11S)-3,7,11,15-tetramethylhexadecyl)cyclohexa-2,5-diene-1,4-dione (IIIc-RRS); 2,3,5-trimethyl-6-((3S,7S,11R)-3,7,11,15-tetramethylhexadecyl)cyclohexa-2,5-diene-1,4-dione (IIIc-SSR); 2,3,5-trimethyl-6-(3S,7R,11S)-3,7,11,15-tetramethylhexadecyl)cyclohexa-2,5-diene-1,4-dione (IIIc-SRS); 2,3,5-trimethyl-6-(3R,7S,11S)-3,7,11,15-tetramethylhexadecyl)cyclohexa-2,5-diene-1,4-dione (IIIc-RSS); 2,3,5-trimethyl-6-(3S,7S,11S)-3,7,11,15-tetramethylhexadecyl)cyclohexa-2,5-diene-1,4-dione (IIIc-SSS); or 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione, or a stereoisomer, a mixture of stereoisomers, a solvate or a hydrate thereof.

### Claim 4 (depends on 1)

The composition according to claim 1, wherein said composition is for reducing the symptoms associated with, or for treating or suppressing autistic spectrum disorder (ASD).

### Claim 5 (depends on 2)

The composition according to claim 2, wherein said composition is for reducing the symptoms associated with, or for treating or suppressing autistic spectrum disorder (ASD).

### Claim 6 (depends on 4)

The composition according to claim 4, wherein the compound is selected from 2-(3-hydroxy-3,7,11,15-tetramethylhexadeca-6,10,14-trienyl)-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione (Ib); Ib-R; Ib-S; 2-(3-hydroxy-3,7,11,15-tetramethylhexadecyl)-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione (Ic); Ic-RRR; Ic-SRR; Ic-RSR; Ic-RRS; Ic-SSR; Ic-SRS; Ic-RSS; Ic-SSS; 2,3,5-trimethyl-6-(3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraenyl)cyclohexa-2,5-diene-1,4-dione (III-b); 2,3,5-trimethyl-6-(3,7,11,15-tetramethylhexadecyl)cyclohexa-2,5-diene-1,4-dione (IIIc); IIIc-RRR; IIIc-SRR; IIIc-RSR; IIIc-RRS; IIIc-SSR; IIIc-SRS; IIIc-RSS; IIIc-SSS; or 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione, or a stereoisomer, a mixture of stereoisomers, a solvate or a hydrate thereof.

### Claim 7 (depends on 1)

The composition according to claim 1, wherein said composition is for reducing the symptoms associated with, or for treating or suppressing attention deficit/hyperactivity disorder (ADHD).

### Claim 8 (depends on 2)

The composition according to claim 2, wherein said composition is for reducing the symptoms associated with, or for treating or suppressing attention deficit/hyperactivity disorder (ADHD).

### Claim 9 (depends on 8)

The composition according to claim 8, wherein the compound is selected from 2-(3-hydroxy-3,7,11,15-tetramethylhexadeca-6,10,14-trienyl)-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione (Ib); Ib-R; Ib-S; 2-(3-hydroxy-3,7,11,15-tetramethylhexadecyl)-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione (Ic); Ic-RRR; Ic-SRR; Ic-RSR; Ic-RRS; Ic-SSR; Ic-SRS; Ic-RSS; Ic-SSS; 2,3,5-trimethyl-6-(3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraenyl)cyclohexa-2,5-diene-1,4-dione (III-b); 2,3,5-trimethyl-6-(3,7,11,15-tetramethylhexadecyl)cyclohexa-2,5-diene-1,4-dione (IIIc); IIIc-RRR; IIIc-SRR; IIIc-RSR; IIIc-RRS; IIIc-SSR; IIIc-SRS; IIIc-RSS; IIIc-SSS; or 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione, or a stereoisomer, a mixture of stereoisomers, a solvate or a hydrate thereof.

### Claim 10

A medical food, a functional food, a food supplement, or a dietary supplement for reducing the symptoms associated with, or for treating or suppressing a pervasive developmental disorder (PDD) or attention deficit/hyperactivity disorder (ADHD), in a patient in need of such treatment; comprising compositions of one or more compounds of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula Ia, Formula IIa, Formula IIIa, Formula IVa, Formula Va, Formula VIa, Formula Ib, Formula Ib-R, Formula Ib-S, Formula Ic, Formula Ic-RRR, Formula Ic-SRR, Formula Ic-RSR, Formula Ic-RRS, Formula Ic-SSR, Formula Ic-SRS, Formula Ic-RSS, Formula Ic-SSS, Formula IIIb, Formula IIIc, Formula IIIc-RRR, Formula IIIc-SRR, Formula IIIc-RSR, Formula IIIc-RRS, Formula IIIc-SSR, Formula IIIc-SRS, Formula IIIc-RSS, Formula IIIc-SSS, Formula Id, Formula IId, Formula IIId, or Formula IVd, and at least one of the group consisting of a physiologically or nutritionally acceptable carrier, adjuvant, excipient, buffer and diluent.

### Claim 11 (depends on 10)

The medical food, functional food, food supplement or dietary supplement according to claim 10, wherein the compound is selected from 2-(3-hydroxy-3,7,11,15-tetramethylhexadeca-6,10,14-trienyl)-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione (Ib); Ib-R; Ib-S; 2-(3-hydroxy-3,7,11,15-tetramethylhexadecyl)-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione (Ic); Ic-RRR; Ic-SRR; Ic-RSR; Ic-RRS; Ic-SSR; Ic-SRS; Ic-RSS; Ic-SSS; 2,3,5-trimethyl-6-(3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraenyl)cyclohexa-2,5-diene-1,4-dione (III-b); 2,3 ,5-trimethyl-6-(3,7,11,15-tetramethylhexadecyl)cyclohexa-2,5-diene-1,4-dione (IIIc); IIIc-RRR; IIIc-SRR; IIIc-RSR; IIIc-RRS; IIIc-SSR; IIIc-SRS; IIIc-RSS; IIIc-SSS; or 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione, or a stereoisomer, a mixture of stereoisomers, a solvate or a hydrate thereof.

### Claim 12 (depends on 10)

A method of reducing the symptoms associated with, or for treating or suppressing a pervasive developmental disorder (PDD) selected from autistic spectrum disorder (ASD), by administering a therapeutically effective amount or physiologically effective amount of the medical food, functional food, food supplement or dietary supplement according to claim 10 to a patient in need thereof.

### Claim 13 (depends on 10)

A method of reducing the symptoms associated with, or for treating or suppressing attention deficit/hyperactivity disorder (ADHD), by administering a therapeutically effective amount or physiologically effective amount of the medical food, functional food, food supplement or dietary supplement according to claim 10 to a patient in need thereof.

### Claim 14

A method of reducing the symptoms associated with, or of treating or suppressing pervasive developmental disorders (PDDs) or attention deficit/hyperactivity disorder (ADHD) in a patient in need of such treatment by administering a therapeutically or physiologically effective amount of one or more compounds of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, or mixtures thereof,
wherein,
the bonds indicated with a dashed line are all single bonds or are all double bonds;
R1, R2, and R3 are independently selected from H, (C1-C6)alkyl, (C1-C6)haloalkyl, (C1-C6)alkoxy, halogen and CN;
or a stereoisomer, a mixture of stereoisomers, a solvate or a hydrate thereof.

### Claim 15 (depends on 14)

The method according to claim 14, comprising administering a therapeutically or physiologically effective amount of one or more compounds of Formula Ia, Formula IIa, Formula IIIa, Formula IVa, Formula Va, Formula VIa, or mixtures thereof,
or a stereoisomer, a mixture of stereoisomers, a solvate or a hydrate thereof, for reducing the symptoms associated with, or for treating or suppressing pervasive developmental disorders (PDDs) or attention deficit/hyperactivity disorder (ADHD) in a patient in need of such treatment.

### Claim 16 (depends on 15)

The method according to claim 15 for reducing the symptoms associated with, or for treating or suppressing pervasive developmental disorders (PDDs) or attention deficit/hyperactivity disorder (ADHD) in a patient in need of such treatment, wherein the administered compound is selected from 2-(3-hydroxy-3,7,11,15-tetramethylhexadeca-6,10,14-trienyl)-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione (Ib); Ib-R; Ib-S; 2-(3-hydroxy-3,7,11,15-tetramethylhexadecyl)-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione (Ic); Ic-RRR; Ic-SRR; Ic-RSR; Ic-RRS; Ic-SSR; Ic-SRS; Ic-RSS; Ic-SSS; 2,3,5-trimethyl-6-(3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraenyl)cyclohexa-2,5-diene-1,4-dione (III-b); 2,3,5-trimethyl-6-(3,7,11,15-tetramethylhexadecyl)cyclohexa-2,5-diene-1,4-dione (IIIc); IIIc-RRR; IIIc-SRR; IIIc-RSR; IIIc-RRS; IIIc-SSR; IIIc-SRS; IIIc-RSS; IIIc-SSS; or 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione, or a stereoisomer, a mixture of stereoisomers, a solvate or a hydrate thereof.

### Claim 17 (depends on 14)

The method according to claim 14, wherein the Pervasive Developmental Disorder (PDD) is autistic spectrum disorder (ASD).

### Claim 18 (depends on 15)

The method according to claim 15, wherein the Pervasive Developmental Disorder (PDD) is autistic spectrum disorder (ASD).

### Claim 19 (depends on 16)

The method according to claim 16, wherein the Pervasive Developmental Disorder (PDD) is autistic spectrum disorder (ASD).

### Claim 20 (depends on 14)

The method according to claim 14, wherein the disorder is attention deficit/hyperactivity disorder (ADHD).

### Claim 21 (depends on 15)

The method according to claim 15, wherein the disorder is attention deficit/hyperactivity disorder (ADHD).

### Claim 22 (depends on 16)

The method according to claim 16, wherein the disorder is attention deficit/hyperactivity disorder (ADHD).

### Claim 23

Use of one or more compounds of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, or mixtures thereof,
wherein,
the bonds indicated with a dashed line are all single bonds or are all double bonds;
R1, R2, and R3 are independently selected from H, (C1-C6)alkyl, (C1-C6)haloalkyl, (C1-C6)alkoxy, halogen and CN;
or a stereoisomer, a mixture of stereoisomers, a solvate or a hydrate thereof;
for reducing the symptoms associated with, or for treating or suppressing pervasive developmental disorders (PDDs) or attention deficit/hyperactivity disorder (ADHD) in a patient in need of such treatment.

### Claim 24 (depends on 23)

The use according to claim 23, of one or more compounds of Formula Ia, Formula IIa, Formula IIIa, Formula IVa, Formula Va, Formula VIa, or mixtures thereof,
or a stereoisomer, a mixture of stereoisomers, a solvate or a hydrate thereof;
for reducing the symptoms associated with, or for treating or suppressing pervasive developmental disorders (PDDs) or attention deficit/hyperactivity disorder (ADHD) in a patient in need of such treatment.

### Claim 25 (depends on 23)

The use according to claim 23, of one or more compounds selected from 2-(3-hydroxy-3,7,11,15-tetramethylhexadeca-6,10,14-trienyl)-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione (Ib); Ib-R; Ib-S; 2-(3-hydroxy-3,7,11,15-tetramethylhexadecyl)-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione (Ic); Ic-RRR; Ic-SRR; Ic-RSR; Ic-RRS; Ic-SSR; Ic-SRS; Ic-RSS; Ic-SSS; 2,3,5-trimethyl-6-(3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraenyl)cyclohexa-2,5-diene-1,4-dione (III-b); 2,3,5-trimethyl-6-(3,7,11,15-tetramethylhexadecyl)cyclohexa-2,5-diene-1,4-dione (IIIc); IIIc-RRR; IIIc-SRR; IIIc-RSR; IIIc-RRS; IIIc-SSR; IIIc-SRS; IIIc-RSS; IIIc-SSS; or 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione, or a stereoisomer, a mixture of stereoisomers, a solvate or a hydrate thereof;
for reducing the symptoms associated with, or for treating or suppressing pervasive developmental disorders (PDDs) or attention deficit/hyperactivity disorder (ADHD) in a patient in need of such treatment.

### Claim 26 (depends on 23)

The use according to claim 23, for reducing the symptoms associated with, or for treating or suppressing a pervasive developmental disorder (PDD) selected from autistic spectrum disorder (ASD).

### Claim 27 (depends on 24)

The use according to claim 24, for reducing the symptoms associated with, or for treating or suppressing a pervasive developmental disorder (PDD) selected from autistic spectrum disorder (ASD).

### Claim 28 (depends on 25)

The use according to claim 25, for reducing the symptoms associated with, or for treating or suppressing a pervasive developmental disorder (PDD) selected from autistic spectrum disorder (ASD).

### Claim 29 (depends on 23)

The use according to claim 23, for reducing the symptoms associated with, or for treating or suppressing attention deficit/hyperactivity disorder (ADHD).

### Claim 30 (depends on 24)

The use according to claim 24, for reducing the symptoms associated with, or for treating or suppressing attention deficit/hyperactivity disorder (ADHD).

### Claim 31 (depends on 25)

The use according to claim 25, for reducing the symptoms associated with, or for treating or suppressing attention deficit/hyperactivity disorder (ADHD).
